Theralink® Technologies Appoints Michael Fanelli
DENVER, Colorado — July 22, 2020 — OncBioMune d/b/a Theralink Technologies (OTC: OBMP), a molecular profiling company specializing in biomarker assay services that target multiple areas of oncology, announced today the appointment of Mr. Michael Fanelli as Senior Director of Biopharma Commerial Operations. Prior to joining Theralink®, Mr. Fanelli was Business Development Executive, Strategic Accounts […]
Theralink® Technologies Launches New Corporate Website
Golden, Colorado – June 17, 2020 – OncBioMune (OTC: OBMP) d/b/a Theralink Technologies, a molecular profiling company, today announced the launch of its new, user-friendly corporate website, https://theralink.com/ OncBioMune recently announced the closing of an asset purchase agreement with Avant Diagnostics with intention to file the necessary application to change the Company name to Theralink® […]
Theralink Technologies and VieCure Announce Strategic Agreement
DENVER, Colorado — July 8th, 2020 — OncBioMune d/b/a Theralink Technologies (OTC: OBMP), a molecular profiling company specializing in biomarker assay services that target multiple areas of oncology, announced today the signing of a multi-year strategic agreement with VieCure™ to enhance personalized cancer treatment in community oncology settings. Theralink Technologies will provide VieCure™ platform users, […]
Theralink Adds Board Members after Stock Purchase Agreement Closes
Golden, Colorado – June 10, 2020 – OncBioMune Pharmaceuticals, Inc. (OTC: OBMP) (“OncBioMune”) today announced the appointment of Mick Ruxin, M.D. as President & CEO and Mr. Jeffrey Busch as Chairman of the Board upon closing of its previously announced asset purchase agreement (Link: https://www.accesswire.com/593012/OncBioMune-Announces-Closing-of-Asset-Purchase-Agreement-with-Avant-Diagnostics). “The closing of this transaction and appointment of Jeff and […]